TaiGen Biopharmaceuticals Holdings Limited
Research TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) on Bullrun: market cap TWD 6.38B, P/E 42.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4157.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 6.38B
- P/E42.7
- Financial periodQ2 2026
- RevenueTWD 8.23M
- Net income-TWD 21.28M
- Free cash flow-TWD 41.59M
- Gross margin50.6%
Valuation Snapshot
latest market cap is TWD 6.38B; P/E is 42.7.
Peer valuation comparison
Latest P/E is 42.67x versus a Healthcare sector median of 21.74x (96.2% above).
Latest P/E is 42.67x versus a Taiwan median of 18.83x (126.6% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 6.38B | 42.7 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About TaiGen Biopharmaceuticals Holdings Limited
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TaiGen Biopharmaceuticals Holdings Limited's market cap?
TaiGen Biopharmaceuticals Holdings Limited's market capitalization is TWD 6.38B.
What is TaiGen Biopharmaceuticals Holdings Limited's P/E ratio?
TaiGen Biopharmaceuticals Holdings Limited's price-to-earnings (P/E) ratio is 42.7.
What does TaiGen Biopharmaceuticals Holdings Limited do?
TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections.